Published in JAMA on July 09, 2008
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol (2010) 1.75
Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) (2010) 1.71
Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes (2010) 1.43
Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One (2010) 1.25
The role of hepatokines in metabolism. Nat Rev Endocrinol (2013) 1.21
Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation (2012) 1.18
Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J (2011) 1.16
Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol (2012) 1.15
Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study. Diabetes Care (2012) 1.06
The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol (2012) 1.06
The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study. J Am Coll Cardiol (2011) 1.05
Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One (2011) 1.02
Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes (2012) 1.00
Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham Heart Study. J Clin Endocrinol Metab (2012) 0.97
Fetuin-A and change in body composition in older persons. J Clin Endocrinol Metab (2009) 0.97
Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med (2012) 0.96
Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J (2015) 0.94
Sex-specific association of fetuin-A with type 2 diabetes in older community-dwelling adults: the Rancho Bernardo study. Diabetes Care (2013) 0.93
Genetically elevated fetuin-A levels, fasting glucose levels, and risk of type 2 diabetes: the cardiovascular health study. Diabetes Care (2013) 0.92
Identification of tuberculosis-associated proteins in whole blood supernatant. BMC Infect Dis (2011) 0.91
Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS One (2014) 0.89
Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study. Nephrol Dial Transplant (2009) 0.88
Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol (2010) 0.88
Plasma fetuin-A concentrations in young and older high- and low-active men. Metabolism (2010) 0.88
Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity (Silver Spring) (2010) 0.87
Fetuin-A: a novel link between obesity and related complications. Int J Obes (Lond) (2014) 0.84
Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2013) 0.84
The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study. BMC Nephrol (2014) 0.82
Association between higher serum fetuin-A concentrations and abnormal albuminuria in middle-aged and elderly chinese with normal glucose tolerance. Diabetes Care (2010) 0.82
Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis (2014) 0.80
Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses' Health Study. J Am Heart Assoc (2014) 0.80
AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity? Curr Obes Rep (2014) 0.80
Adipose Tissue Depots and Their Cross-Sectional Associations With Circulating Biomarkers of Metabolic Regulation. J Am Heart Assoc (2016) 0.79
Can serum fetuin-A be regarded as an inflammatory marker among patients with familial Mediterranean fever? Dig Dis Sci (2013) 0.78
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. PLoS One (2014) 0.78
The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis. Endocrinol Metab (Seoul) (2016) 0.78
Association of fetuin-A level and diabetes risk. JAMA (2008) 0.78
Fetuin-A and risk of coronary heart disease: A Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies. Atherosclerosis (2015) 0.78
Cardiovascular disease in patients with non-alcoholic fatty liver disease. Ann Gastroenterol (2012) 0.78
Fetuin-A, a new vascular biomarker of cognitive decline in older adults. Clin Endocrinol (Oxf) (2014) 0.77
Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin (2016) 0.77
The relationship of fetuin-A and lactoferrin with bone mass in elderly women. Osteoporos Int (2010) 0.77
Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus. Diabetes Metab J (2011) 0.77
Association between alcohol consumption and plasma fetuin-A and its contribution to incident type 2 diabetes in women. Diabetologia (2013) 0.76
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight. Int J Mol Sci (2016) 0.76
Circulating fetuin-A and risk of ischemic stroke in women. Clin Chem (2013) 0.76
Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes. Medicine (Baltimore) (2016) 0.76
The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol (2016) 0.75
Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int J Mol Sci (2016) 0.75
Fetuin-A levels in hyperthyroidism. Clinics (Sao Paulo) (2013) 0.75
Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2016) 0.75
Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. Int J Clin Exp Med (2015) 0.75
Association between fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus. Biomed Rep (2014) 0.75
Fetuin-A Characteristics during and after Pregnancy: Result from a Case Control Pilot Study. Int J Endocrinol (2012) 0.75
Genome-wide Meta-analysis on the Sense of Smell Among US Older Adults. Medicine (Baltimore) (2015) 0.75
Relationship between serum levels of fetuin-A with apo-A1, apo-B100, body composition and insulin resistance in patients with type 2 diabetes. Med J Islam Repub Iran (2014) 0.75
Human Fetuin-A Rs4918 Polymorphism and its Association with Obesity in Healthy Persons and in Patients with Myocardial Infarction in Two Hungarian Cohorts. Med Sci Monit (2016) 0.75
Serum Fetuin-A Associated With Fatty Liver Index, Early Indicator of Nonalcoholic Fatty Liver Disease: A Strobe-Compliant Article. Medicine (Baltimore) (2015) 0.75
Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2016) 0.75
Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise. Physiol Rep (2017) 0.75
Genome-Wide Association Analysis of the Sense of Smell in U.S. Older Adults: Identification of Novel Risk Loci in African-Americans and European-Americans. Mol Neurobiol (2016) 0.75
Association of PPAR Alpha Intron 7 G/C, PPAR Gamma 2 Pro12Ala, and C161T Polymorphisms with Serum Fetuin-A Concentrations. PPAR Res (2017) 0.75
Role of fetuin A in the diagnosis and treatment of joint arthritis. World J Orthop (2017) 0.75
Effects of Exercise Training and Weight Loss on Plasma Fetuin-A Levels and Insulin Sensitivity in Overweight Older Men. J Diabetes Res (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res (1998) 50.73
Prevalence and trends in obesity among US adults, 1999-2000. JAMA (2002) 33.23
Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care (1998) 24.53
The continuing epidemics of obesity and diabetes in the United States. JAMA (2001) 14.84
Analysis of case-cohort designs. J Clin Epidemiol (1999) 5.93
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58
The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest (2003) 3.71
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet (2002) 3.68
Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet (1998) 3.61
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A (2000) 3.44
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 2.99
Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes (1997) 2.76
Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int (2005) 2.42
Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int (2007) 2.42
Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation (2006) 2.27
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2007) 2.23
Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes (2002) 1.99
Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell (1989) 1.96
Computing the Cox model for case cohort designs. Lifetime Data Anal (1999) 1.85
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int (2005) 1.77
Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant (2005) 1.71
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care (2006) 1.57
Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol (1993) 1.50
The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem (1992) 1.49
Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study. Nephrol Dial Transplant (2006) 1.34
Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care (1999) 1.26
Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun (2006) 1.23
Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant (2007) 1.20
Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci (1997) 1.19
Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. Circulation (2002) 1.14
Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol (2001) 1.07
Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem (2007) 1.03
Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med (2007) 1.02
Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. J Biol Chem (1990) 1.01
Fetuin-A is not associated with mortality in chronic kidney disease. Kidney Int (2007) 0.99
Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res (2001) 0.88
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med (2006) 16.17
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci (2006) 7.38
Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med (2013) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA (2006) 6.93
Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation (2005) 6.89
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.54
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study. J Am Geriatr Soc (2005) 6.54
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA (2008) 6.50
Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci (2005) 6.42
Intra-individual change over time in DNA methylation with familial clustering. JAMA (2008) 6.17
Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci (2006) 6.08
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Racial differences in incident heart failure among young adults. N Engl J Med (2009) 5.60
Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med (2002) 5.42
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation (2003) 4.67
The relative safety of ephedra compared with other herbal products. Ann Intern Med (2003) 4.65
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med (2005) 4.57
Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc (2002) 4.55
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol (2003) 4.28
Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry (2010) 4.27
Hearing loss and cognitive decline in older adults. JAMA Intern Med (2013) 4.25
Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care (2003) 4.23
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med (2005) 4.11